Previous 10 | Next 10 |
Cerus Corporation (CERS) Q2 2020 Results Earnings Conference Call August 04, 2020, 04:30 PM ET Company Participants Tim Lee - Investor Relations Nina Mufti - Vice President, Development Obi Greenman - President and Chief Executive Officer Kevin Green - Chief Financial Officer ...
Cerus (NASDAQ: CERS ) : Q2 GAAP EPS of -$0.09 beats by $0.02 . Revenue of $26.8M (+47.2% Y/Y) beats by $6.21M . Shares +5.5% . Press Release More news on: Cerus Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news,
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: Q2 2020 Total Revenue of $26.8 million - driven by robust year-over-year platelet kit sales growth in the U.S. and strong pl...
Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets. The Hong Kong Red Cross BTS is the only public institution providing blood to all hospitals, public and ...
Grifols ( GRFS +1.9% ) announces the delivery of the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin to U.S. healthcare agencies for use in COVID-19 clinical trials, expected to launch in the coming weeks. More news on: Grifols, S.A., Kamada Ltd., XBiotech Inc., ...
Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will dis...
Cerus (NASDAQ: CERS ) announces study results that showed the complete inactivation of the SARS-CoV-2 virus in plasma components intended for transfusion via the use of its INTERCEPT Blood System, a device used by blood banks to reduce the risk of transfusion-transmitted infections from a ...
Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion. These data are consistent with prior INTERCEPT studies showing complete inactiva...
Ultra-thinly traded micro cap Liminal BioSciences ( LMNL +129.1% ) is up on a whopping 105x surge in volume, albeit on a relatively modest 1.2M shares, in reaction to its announcement that subsidiary Prometic Plasma Resources has started collecting convalescent plasma from people who hav...
Carver Bancorp (NASDAQ: CARV ) +232% . More news on: Carver Bancorp, Inc., Urban One, Inc., Energous Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...